1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

In development [GID-TA11023] Expected publication date: 30 April 2025

  • Project information
  • Project documents

30786-Amivantamab-for-Non-Small-Cell-Lung-Cancer-v1.0-MAR22-NON-CONF.pdf (nihr.ac.uk)